The Assisted Reproductive Technology (ART) market is undergoing sustained expansion, driven by rising infertility prevalence, delayed parenthood, and rapidly evolving family structures worldwide. Increasing procedure volumes, growing dominance of IVF and frozen embryo transfers, and expanding access through employer-sponsored fertility benefits are reshaping ART from a specialized medical service into a mainstream healthcare solution.
Chicago, Jan. 27, 2026 (GLOBE NEWSWIRE) — The global assisted reproductive technology market was valued at 30.1 billion in 2024 and is expected to reach US$ 60.7 billion by 2033, growing at a CAGR of 8.1% from 2025 to 2033.
Assisted Reproductive Technology (ART) is rapidly acquiring momentum, which is boosted by several converging factors. Central to this surge is the sharp growth in procedure volumes. Indeed, about 2.5 million ART cycles were initiated worldwide in 2024, with this number anticipated to grow to 2.7 million in 2025.
Request Sample Pages: https://www.astuteanalytica.com/request-sample/assisted-reproductive-technology-market
This steady upward trajectory clearly signals a rising global reliance on ART as a critical solution for infertility challenges. A significant change in clinical preference is evident, with frozen embryo transfers numbering about 1.3 million in 2024, surpassing fresh transfers. Such high volumes indicate a strong and growing patient base seeking solutions.
Changing Family Structures Redefine the Growth Trajectory of Assisted Reproductive Technologies
The drivers behind this demand in the assisted reproductive technology market are deeply demographic and societal. In 2024, the average age of women experiencing a first IVF cycle was 36, while 30 million men were diagnosed with male-factor infertility. These clinical realities are compounded by a broader prevalence, with 1 in 6 heterosexual couples influenced by infertility. The market is also growing beyond conventional models. An estimated 50,000 single parents by choice utilized ART in 2024, and projections show more than 10,000 transgender individuals will utilize fertility preservation by 2025. This diversification represents new and sustainable revenue streams.
Fertility Benefit Platforms Reshape ART Delivery Through Virtual Care and Managed Access
The proliferation of employer-sponsored fertility benefits has become a primary catalyst defining demand in the Assisted Reproductive Technology market. In 2024, more than 450 of the Fortune 500 companies delivered some form of fertility benefit. This corporate adoption is projected to provide more than 12 million employees in the United States access to managed fertility benefits by 2025. The scope of these advantages is also expanding; in 2024 alone, 25 major technology companies added complete surrogacy and adoption advantages. The average lifetime maximum for these benefits presented by large employers stabilized at a strong US$ 25,000 in 2024.
This trend has created a new ecosystem of specialized service providers. The number of dedicated fertility advantage management companies, such as Carrot Fertility and Progyny, grew to more than 30 in 2024. These platforms are seeing high engagement; their networks facilitated more than 500,000 virtual fertility consultations in 2024. The impact is tangible, with an estimated 60,000 employees using their employer-sponsored egg-freezing benefit in 2024. Venture capital is pushing this growth, with fertility benefit startups raising more than US$ 300 million in funding in 2024. This corporate movement is fundamentally moving ART from a prohibitive out-of-pocket expense to an accessible, mainstream employee healthcare alternative.
IVF Dominates Assisted Reproductive Technology Market with 90% Share
The In-Vitro Fertilization (IVF) segment’s dominance, highlighted by its 90% market share, is built on a foundation of continuous innovation and expanding patient access. With more than 3 million cycles performed annually and more than 10 million babies born to date through the procedure, IVF is the cornerstone of modern fertility treatment. The growing adoption of advanced techniques further thickens its position. For instance, Preimplantation Genetic Testing (PGT) is now utilized in more than 400,000 cycles, improving success rates. Investment in technology is also a significant factor, with more than US$ 150 million recently channeled into AI-driven embryo selection platforms. The expansion of treatment alternatives, such as the 200,000 new egg-freezing cycles expected annually and the use of donor eggs in 100,000 cycles, broadens the applications of the assisted reproductive technology market.
This extensive reach is supported by a strong global infrastructure and growing acceptance. Government funding is now available in more than 60 countries, making the treatment more accessible. The field is powered by more than 12,000 specialists, and the use of advanced equipment like time-lapse imaging incubators in 3,000 premier labs shows a commitment to high standards. The assisted reproductive technology market continues to grow, steered by research in areas like in-vitro gametogenesis, which has attracted US$ 50 million in funding, and a rise in fertility tourism, now accounting for 250,000 treatment cycles.
Rising International Patient Inflows Reinforce Europe’s Dominance in Fertility Services
Europe commands the Assisted reproductive technology market with a dominant 35.80% share, functioning as a global hub for fertility services. The region’s leadership is built on immense procedural volumes and a refined clinical infrastructure. Spain presents this, performing more than 165,000 IVF cycles annually, making it the most active ART country in Europe.
This high capacity is supported by a robust professional community, with the number of ESHRE-certified embryologists across the continent surpassing 3,000 in 2024. Furthermore, the region is a leader in cross-border reproductive care; the Czech Republic alone is projected to welcome more than 12,000 international fertility patients in 2025.
The European market is also characterized by its varied but generally supportive legislative frameworks. In 2024, 42 European nations have specific laws governing ART, providing a structured environment for practice. Access is usually enhanced by public funding; 23 countries deliver financial support for at least four IUI cycles. In Germany, the number of fertility clinics reached about 130 in 2024, reflecting a well-distributed network of providers.
Similarly, the UK saw more than 40,000 PGT-A tests performed in 2024. Greece has become a major destination for egg donation, with an estimated 8,000 donor egg cycles performed for international patients in 2024. In France, public health insurance is set to cover costs for an estimated 25,000 new ART cycles in 2025.
Assisted Reproductive Technology Market Major Players:
- California Cryobank
- Cryolab Ltd
- Esco Micro Pte. Ltd
- FUJIFILM Irvine Scientific
- Gynotec
- Hamilton Thorne Ltd.
- Ivy Fertility
- Kitazato Corporation
- Laboratoire CCD
- Liverpool Partners Group
- Merck KGaA
- NidaCon International AB
- Oxford Gene Technology
- Sumitomo Mitsui Financial Group, Inc.
- The Cooper Companies, Inc.
- Thermo Fisher Scientific Inc.
- Vitrolife Group
- Western Fertility Institute
- Other Prominent Players
Key Market Segmentation:
By Type
- In-Vitro Fertilization (IVF)
- Fresh Donor
- Frozen Donor
- Fresh Non-Donor
- Frozen Non-Donor
- Artificial Insemination
- Intrauterine Insemination
- Intracervical Insemination
- Intravaginal Insemination
- Intratubal Insemination
By Product Type
- Women Younger Than Age 35
- Women Older Than Age 35
By End-use
- Fertility Clinics
- Hospitals
- Others
By Region
- North America
- Europe
- Asia Pacific
- Middle East and Africa
- South America
For more information about this report visit: https://www.astuteanalytica.com/industry-report/assisted-reproductive-technology-market
About Astute Analytica
Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements.
With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace.
Contact Us:
Astute Analytica
Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)
For Sales Enquiries: [email protected]
Website: https://www.astuteanalytica.com/
Follow us on: LinkedIn | Twitter | YouTube
CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: [email protected] Website: https://www.astuteanalytica.com/
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.